Review

Impact of Cocoa Consumption on Inflammation Processes—A Critical Review of Randomized Controlled Trials

Sabine Ellinger 1,* and Peter Stehle 2

1 Faculty of Food, Nutrition and Hospitality Sciences Hochschule Niederrhein, University of Applied Sciences, Rheydter Str. 277, Mönchengladbach 41065, Germany
2 Department of Nutrition and Food Sciences, Nutritional Physiology, University of Bonn, Endenicher Allee 11-13, Bonn 53115, Germany; pstehle@uni-bonn.de
* Correspondence: Sabine.Ellinger@hs-niederrhein.de; Tel.: +49-2161-186-5406; Fax: +49-2161-186-5313

Received: 27 February 2016; Accepted: 20 May 2016; Published: 26 May 2016

Abstract: Background: Cocoa flavanols have strong anti-inflammatory properties \textit{in vitro}. If these also occur \textit{in vivo}, cocoa consumption may contribute to the prevention or treatment of diseases mediated by chronic inflammation. This critical review judged the evidence for such effects occurring after cocoa consumption. Methods: A literature search in Medline was performed for randomized controlled trials (RCTs) that investigated the effects of cocoa consumption on inflammatory biomarkers. Results: Thirty-three RCTs were included, along with 9 bolus and 24 regular consumption studies. Acute cocoa consumption decreased adhesion molecules and 4-series leukotrienes in serum, nuclear factor κB activation in leukocytes, and the expression of CD62P and CD11b on monocytes and neutrophils. In healthy subjects and in patients with cardiovascular diseases, most regular consumption trials did not find any changes except for a decreased number of endothelial microparticles, but several cellular and humoral inflammation markers decreased in patients suffering from type 2 diabetes and impaired fasting glucose. Conclusions: Little evidence exists that consumption of cocoa-rich food may reduce inflammation, probably by lowering the activation of monocytes and neutrophils. The efficacy seems to depend on the extent of the basal inflammatory burden. Further well-designed RCTs with inflammation as the primary outcome are needed, focusing on specific markers of leukocyte activation and considering endothelial microparticles as marker of vascular inflammation.

Keywords: cocoa; chocolate; inflammation; randomized controlled trials; evidence; critical review

1. Introduction

Chronic inflammation has been observed in several chronic degenerative diseases beyond rheumatoid arthritis, e.g., in coronary artery disease (CAD) [1], diabetes mellitus [2], age-related macular degeneration [3], Parkinson’s, and Alzheimer’s disease [4]. Chronic inflammation is a decisive risk factor for the development of vascular diseases as it plays a key role in all stages of the formation of vascular lesions and leads to endothelial dysfunction [1]. Biomarkers in serum and plasma like proinflammatory cytokines, adhesion molecules, and acute-phase reactants such as C-reactive protein (CRP) are related to increased risk of cardiovascular events [5] and diabetes-associated vascular impairment [6].

This explains the increasing interest in nutrients with anti-inflammatory properties. A growing body of evidence from \textit{in vitro} studies suggests that nutritive flavanols can modulate the synthesis of pro- and anti-inflammatory metabolites. Flavanols have been shown to reduce the transcription and secretion of adhesion molecules and proinflammatory cytokines (interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α)) [7–10]. Moreover, flavanols increased the production of anti-inflammatory cytokines such as interleukin-4 and interleukin-5 \textit{in vitro} [11]. Since epicatechin, catechin, and dimeric...
procyanidins inhibit the activation of nuclear factor κB (NFκB) in vitro at multiple stages [12,13], the lowered transcription of adhesion molecules and proinflammatory cytokines in vitro may result from changes in redox-sensitive signaling pathways like those of NFκB [14–16]. The inhibition of both lipoxygenases [17,18] and matrix metalloproteinases [19] observed in vitro may contribute to anti-inflammatory effects [20].

Cocoa products are popular foods rich in flavanols. This refers especially to dark chocolate which has the highest flavanol content among flavanol-rich foods per 100 g food [21]. Cocoa products contribute to the four major dietary flavanol sources in Europe [22]. Cocoa flavanols encompass catechin and epicatechin as monomers and procyanidins as oligomers. The procyanidins differ from each other by the number and kind of monomers. In cocoa, oligomers with 4→8 and 4→6 linkages are predominant [21,23]. Increasing evidence suggests that regular cocoa consumption contributes to cardiovascular health by reducing blood pressure [24–28], LDL-cholesterol [25,27,29,30], and insulin resistance [25,27], and by improving vascular elasticity [25,27,28]. These effects are ascribed to cocoa flavanols [25,31–33], especially to epicatechin [34–36]. In the United States, mean flavanol intake was 158 mg/day, estimated from the USDA Flavonoid Database and 24 h dietary recalls from NHANES 1999–2002 [37]. In the EPIC study, average total flavanol intake ranged from 161 mg/day (Greece) to 406 mg/day (UK), an estimation also based on 24-h recall, but considering a larger database (the USDA Flavonoid Database and Phenol-Explorer). In Europe, cocoa products contribute to 5% of total flavanol intake [38], which corresponds to an average intake of 7–19 mg/day.

A cohort study has shown that the consumption of small doses (up to 20 g) of dark chocolate was associated with low concentrations of CRP [39]. However, meta-analyses of randomized controlled trials (RCTs), which included data from five [27] and 10 [25] individual trials, respectively, did not find any changes in CRP by cocoa consumption. These meta-analyses were published in 2011 [27] and 2012 [25], respectively. Up to now, results from RCTs on biomarkers like adhesion molecules and proinflammatory cytokines, known to be involved in different phases of atherosclerosis [5,6,40], have not been assembled yet. The impact of cocoa consumption on inflammation in vivo, based on RCTs, is not clear. In order to evaluate the evidence of anti-inflammatory effects obtained by cocoa consumption, the RCTs’ quality should also be considered.

The aim of this review is to provide a complete overview on the effects of cocoa consumption on markers of inflammation from RCTs with consideration of the quality of the studies to judge the evidence for anti-inflammatory effects in vivo.

2. Materials and Methods

2.1. Literature Search

A systematic literature search was performed in Medline via PubMed for RCTs published between January 2000 and April 2016 that investigated the effects of cocoa-rich food consumption on markers of inflammation. The first search combined the keywords “cocoa” OR “cacao” OR “chocolate” with “inflammation” OR “eicosanoids” OR “adhesion molecule(s)”. The second search combined the keywords “cocoa” OR “cacao” OR “chocolate” with “cardiovascular”. The second search was less specific, but necessary to detect relevant studies that did not focus on inflammation and that were not found by the first search strategy. For the search in PubMed, two filters were applied to restrict the records by type and language to clinical trials published in English or German. In addition to the PubMed search, other sources such as meta-analyses and reviews on the effect of cocoa consumption on inflammation were examined for relevant studies.

2.2. Selection of Trials

The following eligibility criteria were considered:
1. Type of studies: randomized controlled trials
2. Type of interventions: supplementing foods rich in cocoa without restrictions to the kind of food used (e.g., dark chocolate, cocoa-rich drinks, cocoa-enriched foods) or the frequency of supplementation (e.g., single or repeated, daily consumption)
3. Type of controls: supplementing comparable foods lacking cocoa (e.g., white chocolate, milk, placebo drink, foods not enriched with cocoa), being low in cocoa or not providing cocoa-rich foods
4. Type of inflammatory biomarkers: humoral parameters determined in serum or plasma (e.g., CRP, soluble adhesion molecules, eicosanoids, cytokines) and cellular parameters determined in leukocytes obtained from whole blood (e.g., cellular adhesion molecules, immunological functions)

All records identified were checked for duplicates. Duplicates were removed and the remaining records were screened by title and/or abstract to exclude records that did not contribute to answering the question asked in this review. The full-text articles of the remaining records were assessed for eligibility on the basis of the criteria mentioned above.

2.3. Criteria for Judging the Quality of the Selected Trials

The quality of the selected RCTs was judged according to the GRADE criteria. Methodological limitations, e.g., lack of allocation concealment, lack of blinding (participants, researchers), lack of reasons for dropout, no data on compliance, industrial funding, and carryover effects in case of crossover trials were considered. This approach is helpful to assess the quality of evidence more differently by rating down the evidence in case of serious limitations [41,42]. Recording the dietary intake and imposing dietary restrictions on the consumption of other flavanol-rich foods than cocoa may exclude potential side effects and were considered as additional criteria to assess the studies’ quality.

3. Results

Figure 1 provides an overview of the selection of relevant studies. In total, 338 records could be identified. After removing 225 duplicates, the remaining records \( n = 113 \) were screened by title and/or by abstract. This led to the exclusion of 59 records that were considered to be irrelevant to the question addressed by this review. The remaining 54 records were checked for eligibility by the full-text article, leading to the exclusion of 21 articles. Finally, 33 RCTs were included in this review.

These 33 trials were published in 32 different articles. Nine trials investigated the effect of acute cocoa consumption [43–50] (Table 1) and 24 trials addressed the impact of regular, i.e., daily, cocoa consumption on markers of inflammation. The regular consumption trials were further subdivided according to the subjects investigated: trials performed with healthy subjects [51–59] (Table 2), pre-/hypertensive subjects [51,60–62] (Table 3), and trials investigating patients suffering from type 2 diabetes, impaired glucose tolerance [61,63–68] (Table 4), and from CAD [48,69,70] (Table 5). For treatment, most trials used dark chocolate [43,45,47–53,58,59,61,68,69,71] or cocoa drinks rich in flavanols [44,46,50,54,55,57,59,60,62–64,66,67,70,72]. Chocolate or drinks low [43,44,49,55,58,60,62,63,66,70–72] or even free [45–48,50,51,53–57,59,61,64–69] from cocoa mostly served as controls. A few RCTs addressed the effect of flavanol-rich cocoa on postprandial [43,50] or hyperglycemia-induced inflammation [49,66].
whether a cocoa-rich drink consumed together with a high-fat fast-food style meal might affect CRP, but with water. A reduction in ICAM-1 was induced after ingestion of water and milk based cocoa-rich beverages, but concentrations after 6 h were comparably lower after ingestion of the water-based drink. In patients with peripheral artery disease, ingestion of 40 g dark or cocoa-free chocolate did not change CRP. In patients with congestive heart failure and in heart transplant recipients, bolus consumption of 40 g dark chocolate did not change CRP. In type 2 diabetics, a placebo-controlled trial investigating the concentration of NOX2-derived peptide, a marker of NADPH oxidase activity, in serum 2 h after consumption, whereas no changes occurred after consumption of milk chocolate. In patients with peripheral artery disease, ingestion of 40 g dark chocolate reduced the concentration of NOX2-derived peptide, a marker of NADPH oxidase activity, in serum 2 h after consumption, whereas no changes occurred after consumption of milk chocolate. In patients with congestive heart failure and in heart transplant recipients, bolus consumption of 40 g dark or cocoa-free chocolate did not change CRP.

3.1. Bolus Studies

Table 1 provides an overview on bolus studies \( n = 9 \) included in this review. In healthy subjects, the consumption of cocoa-rich food decreased the concentration of leukotrienes \( \text{C}_4, \text{D}_4, \) and \( \text{E}_4 \) in plasma [43], the expression of CD62P (P-selectin) on collagen-activated monocytes and neutrophils [44], and the serum concentration of intercellular adhesion molecule-1 (ICAM-1) and E-selectin [46]. A reduction in ICAM-1 was induced after ingestion of water and milk based cocoa-rich beverages, but concentrations after 6 h were comparably lower after ingestion of the water-based drink. Interestingly, the ratio of P-p65/\( \beta \)-actin in peripheral blood mononuclear cells (PBMC) decreased after consuming the water-based cocoa drink, but not after the milk-based cocoa drink, and even increased after consumption of pure milk. In contrast to ICAM-1, vascular cell adhesion molecule-1 (VCAM-1) did not change after any kind of drink [46]. In healthy non-smokers with prolonged exercise, consumption of 100 g of dark chocolate 2 h prior to prolonged exercise did not change IL-6 in plasma and neutrophils’ respiratory burst and degranulation when compared to the cocoa-free chocolate and fasting conditions [47]. In patients with type 2 diabetes, ingestion of 13.5 g chocolate rich in flavanols 60 min after an oral 75-g-glucose load did not change ICAM-1, E-selectin, P-selectin, and P-selectin-glycoprotein ligand 1 in serum, whereas ICAM-1 increased after ingestion of the same amount of flavanol-poor chocolate [49]. It is important to mention that the differences between pre- and post-consumption values of these four parameters were significantly lower for the flavanol-rich compared to the flavanol-poor chocolate. In type 2 diabetics, a placebo-controlled trial investigating whether a cocoa-rich drink consumed together with a high-fat fast-food style meal might affect CRP, but CRP levels did not change after either intervention, and differences between pre- and post-consumption values could not be observed [50]. In patients with peripheral artery disease, ingestion of 40 g dark chocolate reduced the concentration of NOX2-derived peptide, a marker of NADPH oxidase activity, in serum 2 h after consumption, whereas no changes occurred after consumption of milk chocolate [71]. In patients with congestive heart failure and in heart transplant recipients [45], bolus consumption of 40 g dark or cocoa-free chocolate did not change CRP.
Table 1. Effect of bolus consumption of cocoa on inflammation—results from randomized, controlled trials.

| Study (Reference) | n | Participants | Intervention | EC (mg) | Study Design | Sample | Parameter | Results | Annotations |
|-------------------|---|--------------|--------------|---------|-------------|--------|-----------|---------|-------------|
| Schramm et al., 2001 [43] | 10 | Healthy NS | I: Flavanol-rich chocolate (Dove dark chocolate, Mars), 37 g, consumed with 45 g bagel | I: 41 | Double-blind, crossover | Plasma (0 h, 2 h) | Leukotrienes C4, D4, E4 (sum) | I < C (2 h) | Polyphenol-free diet, 1 week washout |
|                     |    | Age: 39 ± 1 | C: Flavanol-low chocolate (Mars), 37 g, consumed with 45 g bagel | C: 2 | | | | |
|                     |    | BMI: 24.0 ± 0.7 | | | | | | |
|                     |    | CRP: n.d. | | | | | | |
| Heptinstall et al., 2006 [44] | 12 | Healthy subjects | I: Cocoa-rich beverages (CocoaPro, Mars) with different flavanol content: | I: n.d. | Double-blind, crossover | Monocytes from whole blood | CD62P (P-selectin) | I: ▼ | 48 h before low-flavonoid diet, 10 days washout |
|                     |    | Age: n.d. (adults) | I1: 980 mg | | | | | |
|                     |    | BMI: n.d. | I2: 680 mg | | | | | |
|                     |    | CRP: n.d. | I3: 380 mg | | | | | |
|                     |    | | C: Cocoa beverage, low in flavanols (80 mg) | C: n.d. | | | | |
| Flammer et al., 2007 [45] | 22 | Patients with heart transplantation a | I: Flavanol-rich dark chocolate (Nestlé Noir Intense, Nestlé), 40 g | I: 36 | Double-blind, parallel group | Serum (0 h, 2 h) | CRP c | I: o | |
|                     |    | Age: 54 ± 3 | | | | | | |
|                     |    | BMI: 25.7 ± 0.9 | C: Flavanol-free chocolate (Nestlé), 40 g | C: 0 | | | | |
|                     |    | CRP: 5.7 ± 1.9 | | | | | | |
| Davison et al., 2012 [47] | 14 | Healthy NS | I: Flavanol-rich dark chocolate (Nestlé Noir Intense, Nestlé), 100 g | I: 97 | Crossover | Plasma | IL-6 | I: o | Cycling for 2.5 h at 60% maximum O2 uptake |
|                     |    | Age: 22 ± 1 | | | | | | |
|                     |    | BMI: n.d. | | | | | | |
|                     |    | CRP: n.d. | | | | | | |
|                     |    | | C1: Cocoa-free chocolate, 71 g | C1: 0 | | | | |
|                     |    | | C2: No cocoa product | C2: 0 | | | | |
| Flammer et al., 2012 [48] | 20 | Congestive heart failure, NS | I: Flavanol-rich dark chocolate (Nestlé Noir Intense, Nestlé), 28.4 g, weight-matched for fat and sugar content | I: 36 | Double-blind, parallel group | Plasma (0 h, 2 h) | CRP c | I: o | 24 h before low-flavonoid diet |
|                     |    | Age: 59 ± 3 | C: Cocoa-liquor-free chocolate (Nestlé), 28.4 g, weight-matched for fat and sugar content | C: 0 | | | | |
Table 1. Cont.

| Study (Reference) | n  | Participants | Intervention | EC (mg) | Study Design | Sample | Parameter | Results | Annotations |
|-------------------|----|--------------|--------------|---------|-------------|--------|-----------|---------|-------------|
| Mellor et al., 2013 [49] | 10 | Type 2 diabetes, stable, treated with metformin or lifestyle | 1: Flavanol-rich chocolate (Acticoa, Barry Callebaut), 13.5 g, 1 h before an oral glucose load | n.d. | Placebo-controlled, double-blind, crossover | Serum (0 h and 2 h after an oral 75-g-glucose load) | ICAM-1 | I: o C: ↑ | ΔI < ΔC |
| Vázquez-Agell et al., 2013 [46] | 18 | Healthy NS | 1: Cocoa-rich beverages (Nutrexpa) I: 1: with 250 mL milk I: 2: with 250 mL water | I: 28 I: 28 | Crossover | Serum (0 h, 6 h) | E-selectin | I: o C: o | ΔI < ΔC |
| Loffredo et al., 2014 [71] | 20 | Peripheral artery disease 8 | 1: Dark chocolate (≥85% cocoa), 40 g/day C: Milk chocolate (≤35% cocoa), 40 g/day | unclear | Crossover, single-blind | Serum (0 h, 2 h) | NOX2-derived peptide | I: ↓ C: o |
| Basu et al., 2015 [50] | 18 | Type 2 diabetes, stable ≥5 years, no insulin, obese, NS | 1: Cocoa drink, provided in closed lip cups, consumed with a high-fat-fast-food-style breakfast | I: 40 | Double-blind, crossover | Serum (0 h, 0.5 h, 1 h, 2 h, 4 h, 6 h) | CRP 9 | I: o C: o ΔI = ΔC |

a 41% Former smokers, 27% dyslipidemia, 32% hypertension, 18% diabetes, 41% former myocardial infarction or peripheral artery disease; b collagen-induced activation of cells in whole blood *ex vivo*; c determined by high-sensitivity test kits for C-reactive protein; d stimulation with bacterial extract; e measured by elastase; f median and interquartile range in parentheses; g 80% former smokers, 90% dyslipidemia, 85% hypertension, 30% diabetes, 40% coronary heart disease; BMI: body mass index; C: control; CRP: C-reactive protein; EC: epicatechin intake; I: intervention; ICAM-1: intercellular adhesion molecule-1; IL-6: interleukin-6; n.d.: no data available; NS: nonsmoker; VCAM-1: vascular cell adhesion molecule-1; ↑: increase; ↓: decrease; no changes, Δ changes. Data on age (years), BMI (kg/m²), and CRP (mg/L) are means ± SEM if not indicated otherwise. Means were calculated as weighted means from the data of individual groups if not provided by the authors. Missing SEMs were calculated by SDs of individual groups. n refers to the number of participants for whom data on inflammatory markers were available.
### Table 2. Effect of regular cocoa consumption on inflammation in healthy subjects—results from randomized, controlled trials.

| Study (Reference) | n | Participants | Intervention | EC (mg) | IP (d) | Study Design | Sample | Parameter | Results | Annotations |
|-------------------|---|--------------|--------------|---------|--------|--------------|--------|-----------|---------|-------------|
| Grassi et al., 2005 [51] | 20 | Healthy NS  
Age: 34 ± 2  
BMI: 22.6 ± 0.6  
CRP: 0.3 ± 0.1 | I: Dark chocolate (Ritter Sport, Halbbitter, Ritter), 100 g/day  
C: White chocolate (Milka, Kraft Foods), 90 g/day | I: 66  
C: 0 | 15 | Crossover | Serum | CRP * | I: o  
C: o | No flavonoid-rich food, food diaries, 1 week run-in and 1 week washout without chocolate |
| Kurlandsky and Stote, 2006 [52] | 24 | Healthy NS, serum cholesterol 4.1–7.8 mmol/L, no lipid lowering medication  
Age: 43 ± 2  
BMI: 25.0 ± 0.8  
CRP: 4.7 ± 1.5 | I: Dark chocolate (Dove Silky Dark Chocolate, Mars), 41 g/day  
C: No chocolate | n.d. | 42 | Parallel group | Serum | CRP *  
VCAM-1  
ICAM-1 | I: o  
C: o  
I: o  
C: o | Flavonoid-rich food limited, 3 days food records before and in week 2, 4, and 6 of intervention |
| Crews et al., 2008 [53] | 88 | Healthy subjects with prehypertension  
Age: 69 ± 1  
BMI: 25.3 ± 0.5  
CRP: 1.6 ± 0.2 | I: Dark chocolate, 37 g/day, + cocoa beverage, 237 mL/day (Hershey) | n.d. | 42 | Placebo-controlled, double-blind, parallel group | Serum | CRP *  
∆ = ∆C | No flavonoid-rich food, 1 week run-in without flavonoid-rich food, compliance: daily records |
| Njike et al., 2011 [54] | 44 | Healthy NS, overweight/obese  
Age: 52 ± 2  
BMI: 30.2 ± 3.4  
CRP: 0.9 (median) | I: Cocoa-rich beverage with water (Hershey), 454 g/day  
I: sugared  
I: low-flavanol (I2) | I: 48  
I: 48 | 42 | Double-blind, crossover | Serum | CRP *  
VCAM-1  
ICAM-1  
C: 0 | No flavonoid-rich food 24 h before, 3 days food diary during each treatment, 4 weeks washout |
| Tzounis et al., 2011 [55] | 22 | Healthy subjects  
Age: 36 ± 3  
BMI: 23.2 ± 0.4  
CRP: 0.3 ± 0.1 | I: Flavanol-rich cocoa drink (Mars), 150 mL/day  
C: Low-flavanol cocoa drink (Mars), 150 mL/day | I: 89  
C: 3 | 28 | Placebo-controlled, double-blind, crossover | Plasma | CRP * | I: o  
C: o | 2 weeks run-in, 4 weeks washout, no flavonoid-rich food, 4 days food diaries during run-in, 3rd week of both treatments, and during 4th week washout compliance: % used cocoa sachets, self-reported intake >95% |
### Table 2. Cont.

| Study (Reference) | n  | Participants | Intervention | EC (mg) | IP (d) | Study Design | Sample | Parameter | Results | Annotations |
|-------------------|----|--------------|--------------|---------|--------|--------------|--------|-----------|---------|-------------|
| **Ibero-Baraibar et al., 2014 [56]** | 50 | Healthy NS, overweight/obese Age: 57 ± 1 BMI: 30.6 ± 0.3 CRP: n.d. | I: Cocoa extract (1.4 g/day; Nutrafur) in ready-to-eat meals, within a hypocaloric diet (energy restriction of 15%)<sup>1</sup> | I: 153 | 28 | Double-blind, parallel group | Plasma | ICAM-1 | I: ↓ C: ↓ | 1 week run-in without cocoa, 3 days before low-polyphenol-diet; exclude polyphenol-rich foods; compliance >98% |
| | | | C: Ready-to-eat meals not enriched with cocoa extract, within a hypocaloric diet (energy restriction of 15%) | C: 0 | | | | VCAM-1 | I: o C: o | |
| **Sarriá et al., 2014 [57]** | 44 | Healthy NS, normocholesterolemic (<i>n</i> = 24; N) or moderately hypercholesterolemic (<i>n</i> = 20; H) Age: 29 ± 1 BMI: 23.6 ± 0.5 CRP: n.d. | I: Cocoa drink with cocoa, 30 g/day, rich in dietary fiber (Nutrexpa), with 400 mL semi-skimmed milk | I: 9.3 | | | | CRP | n.d. | |
| | | | C: Cocoa-free drink with semi-skimmed milk | C: 0 | 28 | Crossover | Plasma | IL-1β | I: o C: o (N, H) | |
| | | | | | | | | IL-6 | I: o C: o (N, H) | |
| | | | | | | | | IL-8 | I: o C: o (N, H) | |
| | | | | | | | | IL-10 | I: ↓ C: ↓ 1<sub>p</sub> C<sub>p</sub> (N, H) | 2 weeks run-in and during intervention, polyphenol-rich foods were restricted, 3-day food records, compliance measured |
| | | | | | | | | TNF-α | I: o C: o (N, H) | |
| | | | | | | | | MCP-1 | I: o C: o (N, H) | |
| | | | | | | | | VCAM-1 | I: o C: o (N, H) | |
| | | | | | | | | ICAM-1 | I: o C: o (N, H) | |
| **West et al., 2014 [58]** | 13 | Healthy NS, overweight/obese Age: 52 ± 0.3 BMI: 27.8 ± 0.2 CRP: n.d. | I: Dark chocolate, 37 g/day + cocoa drink with 22 g cocoa/day | I: 73.6 | 42 | Placebo-controlled, crossover | Plasma | CRP * | n.d. | 2 days before no flavonoid-rich foods, 2 weeks washout |
| | | | C: Low-flavanol chocolate + cocoa-free drink as color matched control | C: 0.9 | | | | IL-1β | I: o C: o | |
| | | | | | | | | IL-6 | I: o C: o | |
| | | | | | | | | TNF-α | I: o C: o | |
Table 2. Cont.

| Study (Reference) | n  | Participants | Intervention | EC (mg) | IP (d) | Study Design   | Sample      | Parameter | Results | Annotations |
|-------------------|----|--------------|--------------|---------|--------|----------------|-------------|-----------|---------|-------------|
| McFarlin et al., 2015 [59] | 24 | Healthy subjects with normal weight (n = 10; N), overweight (n = 7; O), or obesity (n = 7; B), Age: 22 ± 2, BMI: 21.6 ± 1.9 (N), 27.0 ± 1.4 (O), 34.9 ± 9.9 (B), CRP: n.d. | I: Cocoa bars with 12.7 g natural cocoa (Hershey) C: Cocoa-free placebo bar (Hershey), matched for energy content and macronutrient composition | I: 48.0 C: 0 | 42 | Placebo-controlled, crossover | Serum/Plasma | CRP a | n.d. | no chocolate during study, 2 weeks washout |
|                   |    |              |              |         |        |                |             | AGP      | n.d.   |             |
|                   |    |              |              |         |        |                |             | AMG      | n.d.   |             |
|                   |    |              |              |         |        |                |             | Adipsin  | n.d.   |             |
|                   |    |              |              |         |        |                |             | Haptoglobin | I: o (N,O), 1/2 (B) C: o (N, O, B) | 1/2: B > O > N |
|                   |    |              |              |         |        |                |             | E-selectin | I: o (N, O, B) C: o (N, O, B) | 1/2: B > O > N |
|                   |    |              |              |         |        |                |             | SAP      | n.d.   |             |
|                   |    |              |              |         |        |                |             | Endocan-1 | I: o (N, O, B) C: o (N, O, B) |             |
|                   |    |              |              |         |        |                |             | IL-1β    | n.d.   |             |
|                   |    |              |              |         |        |                |             | IL-6     | n.d.   |             |
|                   |    |              |              |         |        |                |             | IL-8     | n.d.   |             |
|                   |    |              |              |         |        |                |             | TNF-α    | n.d.   |             |
| Study (Reference) | n | Participants | Intervention | EC (mg) | IP (d) | Study Design | Sample | Parameter | Results | Annotations |
|------------------|---|--------------|--------------|---------|-------|-------------|--------|-----------|---------|-------------|
| McFarlin et al., 2015 [59] | 24 | Healthy subjects with normal weight (n = 10; N), overweight (n = 7; O), or obesity (n = 7; B), Age: 22 ± 2 BMI: 21.6 ± 1.9 (N), 27.0 ± 1.4 (O), 34.9 ± 9.9 (B) CRP: n.d. | Cocoa bars with 12.7 g natural cocoa (Hershey) | C: Cocoa-free placebo bar (Hershey), matched for energy content and macronutrient composition | I: 48.0 C: 0 | 42 | Placebo-controlled, crossover | Non-inflammatory monocytes (CD16−) | CD11b | n.d. |
| | | | | | | | | Proinflammatory monocytes (CD16+) | CD11b | n.d. |
| | | | | | | | | All Monocytes | CD62L | I: † (N) o (O), † (B) C: o (N, O, B) t0: B > O > N |
| | | | | | | | | Proinflammatory monocytes (CD16+) | CD62L | I: † (N, O), † (B) C: o (N, O, B) t0: B > O > N |
| | | | | | | | | EMP in whole blood | EMP concentration | I: o (N, O), † (B) C: o (N, O, B) t0: B > O > N |

* determined by high-sensitivity test kits for C-reactive protein. AGP: alpha-2 acid glycoprotein; AMP: alpha-2 macroglobulin; B: obese; BMI: body mass index; C: control; C\(_{IP}\): value after intervention; d: days; CRP: C-reactive protein; EC: epicatechin; EMP: endothelial microparticles (CD42a-/45-/144+); H: hypercholesterolemic; I: intervention; IP: intervention period; IL: interleukin; \( \Delta \): value after intervention; ICAM-1: intracellular adhesion molecule 1; IL-1β: interleukin-1β; IL-6: interleukin-6; n.d: no data available; NS: non-smoker; MCP-1: monocyte chemoattractant protein-1; N: normocholesterolemic; O: overweight; SAP: serum amyloid P; TNF-α: tumor necrosis factor-α; VCAM-1: vascular cell adhesion molecule-1; wk: week; †: increase; †: decrease; o: no changes, \( \Delta \): difference pre- vs. post-consumption value. Data on age (years), BMI (kg/m\(^2\)), and CRP (mg/L) are means ± SEM if not indicated otherwise. Means were calculated as weighted means from the data of individual groups if not provided by the authors. Missing SEMs were calculated by SDs of individual groups. n refers to the number of participants for which data on inflammatory markers were available.
### Table 3. Effect of regular cocoa consumption on inflammation in patients with pre-/hypertension—results from randomized, controlled trials.

| Study (Reference) | n  | Participants                          | Intervention                                                                 | EC (mg) | IP (d) | Study Design | Sample   | Parameter | Results | Annotations                                      |
|-------------------|----|---------------------------------------|------------------------------------------------------------------------------|---------|--------|--------------|----------|-----------|---------|--------------------------------------------------|
| Grassi et al., 2005 [51] | 20 | Untreated grade I hypertension, NS Age: 44 ± 2 BMI: 25.4 ± 0.3 CRP: 0.4 ± 0.1 | I: Flavanol-rich dark chocolate (Ritter Sport Halbbitter, Ritter), 100 g/day | I: 66   | 15     | Crossover    | Serum    | CRP ¹   | I: o     | C: o                       | No flavonoid-rich food, Food diaries, 1 week chocolate free run-in and washout |
|                    |    |                                       | C: White chocolate (Milka, Kraft Foods), 90 g/day, matched for energy, macro-, micronutrients | C: 0    |         |              |          |           |         |                                                   |
| Wang-Polagruto et al., 2006 [60] | 32 | Hypertension stage I or prehypertension, hypercholesterolemia, NS Age: 57 ± 1 BMI: 25.1 ± 0.6 CRP: n.d. | I: Flavanol-rich cocoa drink with 18.8 g cocoa powder (Mars), sucrose, 240 mL/day | n.d.    | 42     | Double-blind, parallel group | Plasma   | E-selectin | I: o | C: o | No flavonoid-rich food 24 h before study, 2 weeks run-in with flavanol-poor cocoa drink, 3 × 3 days Food records, Compliance: empty packets |
|                    |    |                                       | C: Flavanol-poor cocoa drink, 240 mL/day                                     | n.d.    |         |              |          | ICAM-1   | I: o     | C: o |                                                   |
|                    |    |                                       |                                                                               |         |         |              |          | VCAM-1   | I: ∆    | C: ∆ | ∆I > ∆C                                          |
| Grassi et al., 2008 [61] | 19 | Untreated stage I hypertension, impaired glucose tolerance, NS Age: 45 ± 1 BMI: 26.5 ± 0.3 CRP: n.d. | I: Flavanol-rich chocolate (Cuorenero, Sugar Company), 100 g/day | I: 111  | 15     | Crossover    | Serum    | CRP ²   | I: o     | C: o | No flavonoid-rich food, 1 week cocoa-free run-in and washout, Food records daily |
|                    |    |                                       | C: White chocolate (Milka, Kraft Foods), 100 g/day                           | C: 0    |         |              |          |           |         |                                                   |
| Muniyappa et al., 2008 [62] | 20 | Stage 1 hypertension, overweight/obesity, NS, antihypertensive medication (n = 6) discontinued Age: 51 ± 2 BMI: 33.2 ± 1.4 CRP: n.d. | I: Flavanol-rich cocoa drink with cocoa powder (CocoaPro, Mars), water, 300 mL/day | I: 174  | 14     | Placebo-controlled, double-blind, crossover | Serum or plasma | E-selectin | I: o | C: o | 1 week Run-in and 1 week washout with low-flavanol diet, Compliance: cocoa powder or placebo packets |
|                    |    |                                       | C: Flavanol-poor placebo drink, with water, matched for energy, macronutrients, similar in color, taste and packaging, 300 mL/day | C: 0    |         |              |          | ICAM-1   | I: o    | C: o |                                                   |
|                    |    |                                       |                                                                               |         |         |              |          | VCAM-1   | I: o     | C: o |                                                   |
|                    |    |                                       |                                                                               |         |         |              |          | MCP-1    | I: o     | C: o |                                                   |
|                    |    |                                       |                                                                               |         |         |              |          | IL-6     | I: o     | C: o |                                                   |
|                    |    |                                       |                                                                               |         |         |              |          | TNF-α    | I: o     | C: o |                                                   |

¹ determined by high-sensitivity test kits for C-reactive protein. BMI: body mass index; C: control; d: days; CRP: C-reactive protein; EC: epicatechin; I: cocoa intervention; ICAM-1: intercellular adhesion molecule-1; I: cocoa intervention; IL-6: interleukin-6; IP: intervention period; n.d.: no data available; MCP-1: monocyte chemotactrant protein-1; TNF-α: tumor necrosis factor-α; VCAM-1: vascular cell adhesion molecule-1; ∆: decrease; o: no changes; Δ difference pre- vs. post-consumption values. Data on age (years), BMI (kg/m²), and CRP (mg/L) are means ± SEM. Means were calculated as weighted means from the data of individual groups if not provided by the authors. Missing SEMs were calculated by SDs, of individual groups. n refers to the number of participants for whom data on inflammatory markers were available.
Table 4. Effect of regular cocoa consumption on inflammation in patients with type 2 diabetes or impaired glucose tolerance—results from randomized, controlled trials.

| Study (Reference) | n  | Participants | Intervention | EC (mg) | IP (d) | Study Design | Sample | Parameter | Results | Annotations |
|-------------------|----|--------------|--------------|---------|--------|--------------|--------|-----------|---------|-------------|
| Balzer et al., 2008 [63] | 41 | Type 2 diabetes, stably-treated, NS Age: 64 ± 1 BMI: 31.6 ± 0.8 CRP: 4.9 ± 1.1 | I: Flavanol-rich cocoa drink, with CocoaPro cocoa powder (Mars), 750 mL/day | 1: 203 | 30 | Double-blind, parallel group | Plasma | CRP | I: o C: o | No dietary restrictions, dietary intake not determined, compliance: empty cocoa sachets, epicatechin in plasma |
| Grassi et al., 2008 [61] | 19 | Impaired glucose tolerance, untreated stage I hypertension, NS Age: 45 ± 1 BMI: 26.5 ± 0.3 CRP: n.d. | I: Flavanol-rich chocolate (Cuorenero, Sugar Company), 100 g/day | I: 111 | 15 | Crossover | Serum | CRP | I: o C: o | No flavonoid-rich food, 1 week cocoa-free run-in and washout, food records daily |
### Table 4. Cont.

| Study (Reference) | n  | Participants | Intervention | EC (mg) | IP (d) | Study Design | Sample | Parameter      | Results | Annotations |
|-------------------|----|--------------|--------------|---------|--------|-------------|--------|----------------|---------|-------------|
| Monagas et al., 2009 [64] | 42 | Diabetes or ≥3 cardiovascular disease risk factors (smoking, hypertension, hypercholesterolemia, obesity, family history of premature coronary heart disease) Age: 70 ± 2 BMI: 27.6 ± 0.8 CRP: 0.5 ± 0.3 | I: Cocoa drink, prepared with cocoa powder (Nutrexpa) and skim milk, 500 mL/day | 46 | 28 | Crossover | | CRP | I: 0 C: 0 | |
|                   |    |              |              |         |        |             |        | P-selectin     | I: ↓ C: 0 | I < C (d28) |
|                   |    |              |              |         |        |             |        | E-selectin     | I: 0 C: 0 | |
|                   |    |              |              |         |        |             |        | ICAM-1         | I: ↓ C: 0 | I < C (d28) |
|                   |    |              |              |         |        |             |        | VCAM-1         | I: 0 C: 0 | |
|                   |    |              |              |         |        |             |        | MCP-1          | I: 0 C: 0 | |
|                   |    |              |              |         |        |             |        | IL-6           | I: 0 C: 0 | |
|                   |    |              |              |         |        |             |        | LFA-1          | I: 0 C: 0 | |
|                   |    |              |              |         |        |             |        | Mac-1          | I: 0 C: 0 | |
|                   |    |              |              |         |        |             |        | VLA-4          | I: ↓ C: 0 | I < C (d28) |
|                   |    |              |              |         |        |             |        | SLeα           | I: 0 C: 0 | |
|                   |    |              |              |         |        |             |        | CD36           | I: ↓ C: 0 | I < C (d28) |
|                   |    |              |              |         |        |             |        | CD40           | I: ↓ C: 0 | I < C (d28) |
|                   |    |              |              |         |        |             |        | LFA-1          | I: 0 C: 0 | |
|                   |    |              |              |         |        |             |        | VLA-4          | I: 0 C: 0 | |
|                   |    |              |              |         |        |             |        | SLeα           | I: 0 C: 0 | |
|                   |    |              |              |         |        |             |        | CD40           | I: 0 C: 0 | |

Flavonoid-rich food limited, 3 x 3 days food records, compliance: patient reports and epicatechin metabolites in plasma and urine, 2 weeks run-in, no washout-period.
### Table 4. Cont.

| Study (Reference)                  | n   | Participants                          | Intervention                                                                 | EC (mg) | IP (d) | Study Design | Sample          | Parameter       | Results | Annotations                                    |
|-----------------------------------|-----|---------------------------------------|------------------------------------------------------------------------------|---------|--------|--------------|----------------|----------------|---------|-----------------------------------------------|
| Mellor et al., 2010 [65]          | 12  | Type 2 diabetes, no steroids, no changes in chronic medication | Age: 68 (median); 42–71 (range) BMI: n.d. CRP: 2.8 ± 0.5                  |         |        | Double-blind, crossover | Serum or plasma | CRP *           | I: o   | C: o 4 weeks washout, compliance: empty wrappers: 93.8%, no changes in diet and lifestyle, dietary recalls |
| Stote et al., 2012 [66]           | 19  | Impaired or normal glucose tolerance, obese, NS | Age: 46 ± 1 BMI: 36.8 ± 0.2 CRP: n.d.                                      |         |        | Single-blind, crossover | Serum or plasma (0, 0.5, 1, 1.5, 2.0 h after an oral 75-g-glucose load) | CRP * | I: by dose | ICAM-1 o by dose | 10 days washout, no dietary changes |
| Parsaean et al., 2014 [67]        | 100 | Type 2 diabetes | Age: 54 ± 1 BMI: 28 ± 0.5 CRP: n.d.                                         |         |        | Parallel group | Serum          | CRP *           | I: by dose | C: o | Dietary records, no restrictions |
| Rostami et al., 2015 [68]         | 60  | Type 2 diabetes, blood pressure ≥140/90 mm Hg, stable medication, NS | Age: 60 ± 1 BMI: 29.8 ± 0.6 CRP: unclear                                    |         |        | Placebo-controlled, double-blind, parallel group | Serum          | CRP * | I: by dose | C: o | No effect by ANCOVA adjusted for age, sex, energy intake | No further chocolate, 3 days food records |

* determined by high-sensitivity test kits for C-reactive protein. BMI: body mass index; C: control; d: days; CRP: C-reactive protein; EC: epicatechin; I: cocoa intervention; ICAM-1: intercellular adhesion molecule-1; IL-6: interleukin-6; IP: intervention period; LFA-1: lymphocyte function-associated antigen-1; MCP-1: monocyte chemotactic protein; n.d.: no data available; SLE*: sialil Lewis X, CD15s; VCAM-1: vascular cell adhesion molecule-1; VLA-4: very late activation antigen-4; ∆: decrease; o: no changes; Δ difference pre- vs. post-consumption values. Data on age (years), BMI (kg/m²), and CRP (mg/L) are means ± SEM if not indicated otherwise. Means were calculated as weighted means from the data of individual groups if not provided by the authors. Missing SEMs were calculated by SDs, of individual groups. n refers to the number of participants for whom data on inflammatory markers were available.
Table 5. Effect of regular cocoa consumption on inflammation in patients with coronary heart disease—results from randomized, controlled trials.

| Study (Reference) | n | Participants | Intervention | EC (mg) | IP (d) | Study Design | Sample | Parameter | Results | Annotations |
|-------------------|---|--------------|--------------|---------|-------|-------------|--------|-----------|---------|-------------|
| Farouque et al., 2006 [69] | 40 | Coronary artery disease, 55% with hypertension, 85% with hypercholesterolemia, mostly medically treated | I: Flavanol-rich chocolate (48 g/day, Mars) + one cocoa beverage per day (Mars) | 1:07 | 42 | Placebo-controlled, double-blind, crossover | Plasma | CRP a | I: o C: o | No dietary restrictions, dietary intake not determined, compliance: wrapper amount and patient reports |
| | | | | | | | | P-selectin | I: o C: o |
| | | | | | | | E-selectin | I: o C: o |
| | | | | | | | ICAM-1 | I: o C: o |
| | | | | | | | VCAM-1 | I: o C: o I: < C (d42) |
| | | | | | | | EMP (CD41+) | I: o C: o |
| | | | | | | | EMP (CD144+) | I: o C: o I: < C (d42) |
| Heiss et al., 2010 [70] | 16 | Coronary artery disease, medically treated, NS | I: Flavanol-rich cocoa drink with CocoaPro cocoa powder (Mars), 2 drinks/day, prepared with skim milk or water | 1:39 | 30 | Double-blind, crossover | Plasma | CRP a | I: o C: o |
| | | | | | | | Peripheral blood mononuclear cells | Chemotaxis | I: o C: o |
| | | | | | | | | 1 week washout |
| Flammer et al., 2012 [48] | 20 | Congestive heart failure, NS | I: Flavanol-rich dark chocolate (Nestlé Noir Intense, Nestlé), 40 g/day | 1:36 | 28 | Double-blind, parallel group | Plasma | CRP a | I: o C: o 24 h before flavonoid-low diet |
| | | | | | | | | EMP (CD41+) | I: o C: o |
| | | | | | | | | EMP (CD144+) | I: o C: o I: < C (d42) |
| Horn et al., 2014 [72] | 16 | Coronary artery disease, NS, medically treated, 38% diabetes, 88% hypertension, 85% hyperlipidemia, 63% prior smoking | I: Flavanol-rich cocoa drink with cocoa powder (Mars), 2 drinks/day | 1:118 | 30 | Double-blind, crossover | Plasma | EMP (CD41+) | I: o C: o |
| | | | | | | | | EMP (CD144+) | I: o C: o I: < C (d42) |

* determined by high-sensitivity test kits for C-reactive protein. BMI: body mass index; C: control; d: days; CRP: C-reactive protein; EC: epicatechin; EMP: endothelial microparticles; I: cocoa intervention; ICAM-1: intercellular adhesion molecule-1; IL-6: interleukin-6; IP: intervention period; n.d.: no data available; PMP: platelet-derived microparticles; VCAM-1: vascular cell adhesion molecule-1; ∆: decrease; o: no changes; Δ difference pre- vs. post-consumption values. Data on age (years), BMI (kg/m²), and CRP (mg/L) are means ± SEM if not indicated otherwise. Means were calculated as weighted means from the data of individual groups if not provided by the authors. Missing SEMs were calculated by SDs, of individual groups. n refers to the number of participants for whom data on inflammatory markers were available.
3.2. Studies on Regular Cocoa Consumption

3.2.1. Healthy Subjects

Table 2 provides an overview of studies \(n = 9\) that investigated the impact of regular consumption of cocoa-rich products on markers of inflammation in serum or plasma in healthy subjects after an overnight fast. ICAM-1 decreased after daily consumption of dark chocolate (41 g/day) for 42 weeks [52], but not after providing 100 g/day chocolate for 15 days [51] or 400 mL/day of a cocoa-rich beverage for 28 days [57]. In the study of Ibero-Baraibar et al. [56], ICAM-1 decreased by consumption of ready-to-eat-meals irrespective if these were enriched with cocoa extract or not. However, these meals were part of a hypocaloric diet with an energy restriction about 15% of total energy expenditure [56]. Regular cocoa consumption did not change VCAM-1 in any study [52,56,57]. Changes in proinflammatory cytokines (IL-1\(\beta\), IL-6, TNF-\(\alpha\)) were not observed [57,58].

The concentration of chemokines in plasma (IL-8, monocyte chemoattractant protein-1) was not modulated by 4-week consumption of a cocoa drink [57]. However, interleukin-10 decreased after intervention with cocoa-rich and cocoa-free drinks, but the changes induced by the cocoa drink were significantly lower than those of the cocoa-free control [57]. In most trials that determined serum CRP concentrations, changes did not occur due to regular cocoa consumption [51–54,57,58]. Only Tzounis et al. found a decrease in CRP after 4-week consumption of a flavanol-rich cocoa drink, which was accompanied by significantly lower post-consumption values compared to the low-flavanol cocoa drink [55]. In three studies, results on CRP were not reported [57–59]. In another study [59], reduced concentrations of haptoglobin and endothelial microparticles in serum and plasma, respectively, and a lower expression of CD62L (L-selectin) on monocytes after 4-week consumption of cocoa-rich bars were observed in obese subjects, but not in similar aged subjects who were normal weight or overweight. In obese subjects, a trend towards reduced levels of endocan-1 (also called endothelial cell specific molecule-1) and E-selectin in serum after cocoa consumption could be observed, which, however, did not reach significance. At baseline, the concentrations of haptoglobin, E-selectin, and endothelial microparticles were significantly higher in obese subjects compared to normal-weight and overweight subjects. Moreover, obese participants initially had a higher expression of CD62L on monocytes than participants who were normal weight or overweight.

3.2.2. Pre-/Hypertensive Subjects

The results of RCTs performed with pre-/hypertensive subjects are shown in Table 3. In patients with untreated stage I hypertension, daily consumption of 100 g dark chocolate for 15 days did not affect ICAM-1 [51] and CRP [51,61]. Consumption of flavanol-rich cocoa drinks for two [62] or six weeks [60], respectively, did not change E-selectin [60,62], P-selectin [60], ICAM-1, VCAM-1, monocyte chemoattractant protein-1 (MCP-1), IL-6, or TNF-\(\alpha\) [62] in serum or plasma. The only significant change observed concerned VCAM-1 in the study of Wang-Polagruto et al. [60]. Here, VCAM-1 decreased after six weeks’ ingestion of a cocoa-rich drink and the differences between pre- and post-consumption values were higher after consuming the cocoa-rich compared to the control drink.

3.2.3. Patients with Type 2 Diabetes or Impaired Glucose Tolerance

Studies with patients suffering from type 2 diabetes or impaired glucose tolerance are shown in Table 4. Daily administration of flavanol-rich chocolate (25 g [68], 45 g [65], 100 g [61]) for 5–56 days compared to white chocolate did not change CRP. Most studies providing cocoa-rich beverages observed anti-inflammatory effects: Parsaeyan et al. found a decrease in CRP, IL-6, and in TNF-\(\alpha\) after six weeks [67]. Stote et al. [66] provided water-based beverages with different amounts of flavanols for five days to a group of obese patients who suffered from impaired glucose tolerance. Before and after intervention, an oral 75-g-glucose load was given and a significant decrease in ICAM-1, IL-6, and in CRP by ingestion of the cocoa drink was observed, dependent on the dose of flavanols ingested. Balzer et al. [63] also provided flavanol-rich cocoa, but did not find any changes in CRP. However, this
was the only inflammatory biomarker determined in this trial. Monagas et al. [64], who investigated a mixed group of patients (diabetics and patients with at least three cardiovascular disease risk factors such as smoking, hypertension, hypercholesterolemia, obesity, and a family history of premature coronary disease), provided 500 mL/day of a flavanol-rich cocoa drink, based on milk, and pure milk as a control for 28 days. Cocoa consumption reduced the concentration of several adhesion molecules in plasma (ICAM-1, P-selectin) and on monocytes (very late antigen-4; VLA-4; CD49d), and the expression of CD36 and CD40 on monocytes. For these parameters, differences between pre- and post-consumption values were significantly higher after consumption of cocoa-rich cocoa compared to milk. E-selectin, VCAM-1, MCP-1, IL-6, and CRP in serum or plasma and lymphocyte function-associated antigen-1 (LFA-1; CD11a), Mac-1 (CD11b/CD18), Sialil Lewis X (SLe\textsuperscript{x}; CD15s) on monocytes did not change. The expression of LFA-1, VLA-4, SLe\textsuperscript{x}, and CD40 on T cells was not modulated by cocoa intervention either.

3.2.4. Patients with Coronary Heart Disease

In patients suffering from CAD [69,70,72] and congestive heart failure [48] (Table 5), daily ingestion of flavanol-rich chocolate [48,69] or cocoa [70,72] for 28–42 days did not change CRP [48,69,70], P-selectin, E-selectin, ICAM-1, or VCAM-1 [69]. However, VCAM-1 was significantly higher before the consumption of flavanol-rich chocolate compared to isocaloric placebo. This difference was no longer significant after six weeks of intervention [69]. Chemotaxis of PBMC was not modulated by consumption of flavanol-rich cocoa [70]. The number of endothelial microparticles (CD144+ as well as CD31+/CD41- subpopulation) decreased significantly after ingestion of flavanol-rich cocoa drinks and reached lower concentrations after 30 days of intervention compared to the placebo drinks. At baseline, CAD patients had more CD31+/CD41- endothelial microparticles in blood than age-matched and younger healthy controls, whereas the number of CD144+ endothelial microparticles differed only between young and old subjects, but not between CAD patients and age-matched healthy controls. In contrast to endothelial microparticles, the number of platelet-derived microparticles (CD41+) was not affected by cocoa treatment [72].

3.3. Quality of Selected Studies

Table 6 provides an overview on qualitative criteria of the selected trials. Seventy percent of them had crossover and 30% had a parallel group design. Masking of researchers and participants was ensured in 82% and 61% of all RCTs, respectively. Information on allocation concealment was lacking in half of all studies. Dropout was clearly reported in most studies with regular cocoa consumption and also in bolus studies if patients were lost, but this did rarely occur. Forty percent of all studies were funded by industry and most trials received the cocoa products as gifts from industry (82%). In bolus studies, compliance was not reported as cocoa products were always ingested in the study center. Only 50% of regular consumption studies determined adherence to dietary treatment. Carry-over effects could be excluded in most trials with crossover design by washout periods. About 45% of all studies recorded dietary intake and 76% provided dietary restrictions to prevent confounding effects.
Table 6. Quality of randomized controlled studies.

| Study (Reference) | Allocation Concealment | Masking of Participants | Masking of Researchers | Dropouts Clearly Reported | Industry Funding | Cocoa Products as Gift from Industry | Compliance Measured | Crossover Design | Carry-Over Effects Possible * | Dietary Intake Documented | Dietary Restrictions |
|-------------------|-------------------------|-------------------------|------------------------|--------------------------|------------------|-------------------------------------|--------------------|----------------|-------------------------------|---------------------------|------------------------|
| Bolus consumption |                         |                         |                        |                          |                  |                                     |                    |                |                               |                          |                        |
| Schramm et al., 2001 [43] | Y                      | Y                      | Y                      | Y                        | Y                | Y                                   | Y                  | N              | Y                             | N                         | Y                      |
| Heptinstall et al., 2006 [44] | ?                     | Y                      | Y                      | Y                        | Y                | Y                                   | Y                  | N              | Y                             | N                         | Y                      |
| Flammer et al., 2007 [45] | Y                      | Y                      | Y                      | Y                        | Y                | Y                                   | Y                  | N              | Y                             | N                         | Y                      |
| Davison et al., 2012 [47] | Y                      | Y                      | Y                      | Y                        | Y                | Y                                   | Y                  | N              | Y                             | N                         | Y                      |
| Flammer et al., 2012 [48] | Y                      | Y                      | Y                      | Y                        | Y                | Y                                   | Y                  | N              | Y                             | N                         | Y                      |
| Müller et al., 2013 [49] | Y                      | Y                      | Y                      | Y                        | Y                | N                                   | Y                  | N              | Y                             | N                         | Y                      |
| Vlaar-Apoo et al., 2013 [46] | ?                     | N                      | Y                      | N                        | Y                | Y                                   | Y                  | N              | Y                             | N                         | Y                      |
| Loffreda et al., 2014 | Y                      | N                      | Y                      | Y                        | Y                | Y                                   | Y                  | N              | Y                             | N                         | Y                      |
| Bass et al., 2015 [50] | ?                     | Y                      | Y                      | Y                        | Y                | Y                                   | Y                  | N              | Y                             | N                         | Y                      |
| Regular consumption—healthy |                         |                         |                        |                          |                  |                                     |                    |                |                               |                          |                        |
| Grans et al., 2005 [51] | ?                     | N                      | N                      | Y                        | N                | Y                                   | Y                  | N              | Y                             | N                         | Y                      |
| Kosandak and Nokte, 2006 [52] | Y                      | N                      | N                      | Y                        | Y                | N                                   | Y                  | N              | Y                             | N                         | Y                      |
| Croes et al., 2008 [53] | Y                      | Y                      | Y                      | Y                        | Y                | N                                   | Y                  | N              | -                             | Y                         | Y                      |
| Nakao et al., 2011 [54] | Y                      | Y                      | Y                      | Y                        | Y                | Y                                   | Y                  | N              | N                             | Y                         | Y                      |
| Townes et al., 2011 [55] | Y                      | Y                      | Y                      | Y                        | Y                | Y                                   | Y                  | N              | Y                             | N                         | Y                      |
| Bano-Barnal et al., 2013 [56] | ?                     | Y                      | Y                      | Y                        | N                | Y                                   | Y                  | N              | -                             | Y                         | Y                      |
| Sarti et al., 2014 [57] | N                      | N                      | N                      | Y                        | Y                | Y                                   | Y                  | Y              | Y                             | Y                         | Y                      |
| West et al., 2014 [58] | ?                     | Y                      | Y                      | Y                        | Y                | Y                                   | Y                  | N              | N                             | N                         | Y                      |
| McCafé et al., 2013 [59] | ?                     | Y                      | Y                      | Y                        | Y                | N                                   | Y                  | Y              | N                             | N                         | Y                      |
| Regular consumption—pre-/hypertension |                         |                         |                        |                          |                  |                                     |                    |                |                               |                          |                        |
| Grans et al., 2005 [51] | ?                     | N                      | N                      | Y                        | N                | Y                                   | Y                  | N              | Y                             | N                         | Y                      |
| Wang-Falgarito et al., 2006 [60] | ?                     | Y                      | Y                      | Y                        | Y                | Y                                   | Y                  | N              | Y                             | N                         | Y                      |
| Grans et al., 2006 [61] | ?                     | N                      | Y                      | Y                        | N                | Y                                   | Y                  | Y              | -                             | Y                         | Y                      |
| Mantyppa et al., 2008 [62] | Y                      | Y                      | Y                      | Y                        | Y                | Y                                   | Y                  | N              | Y                             | N                         | Y                      |
| Regular consumption—diabetes, impaired glucose tolerance |                         |                         |                        |                          |                  |                                     |                    |                |                               |                          |                        |
| Balzer et al., 2006 [63] | ?                     | Y                      | Y                      | Y                        | Y                | Y                                   | Y                  | N              | N                             | Y                         | N                      |
| Grans et al., 2008 [61] | ?                     | N                      | Y                      | Y                        | N                | Y                                   | Y                  | Y              | Y                             | Y                         | Y                      |
| Meraglia et al., 2009 [64] | ?                     | N                      | Y                      | Y                        | Y                | Y                                   | Y                  | Y              | Y                             | Y                         | Y                      |
| Müller et al., 2010 [65] | Y                      | Y                      | Y                      | Y                        | Y                | Y                                   | Y                  | N              | Y                             | Y                         | Y                      |
| Stol et al., 2012 [66] | ?                     | N                      | Y                      | Y                        | N                | Y                                   | Y                  | N              | Y                             | Y                         | Y                      |
| Parastar et al., 2014 [67] | N                     | N                      | N                      | N                        | N                | N                                   | Y                  | N              | Y                             | N                         | Y                      |
| Estani et al., 2015 [68] | Y                     | N                      | Y                      | Y                        | N                | Y                                   | Y                  | N              | N                             | Y                         | Y                      |
| Regular consumption—coronary heart disease |                         |                         |                        |                          |                  |                                     |                    |                |                               |                          |                        |
| Farniu et al., 2008 [69] | Y                      | Y                      | Y                      | N                        | Y                | Y                                   | Y                  | Y              | Y                             | N                         | N                      |
| Hems et al., 2010 [70] | ?                     | Y                      | Y                      | Y                        | Y                | Y                                   | Y                  | N              | Y                             | N                         | N                      |
| Flammer et al., 2012 [48] | Y                     | Y                      | Y                      | Y                        | Y                | Y                                   | Y                  | N              | N                             | N                         | Y                      |
| Hems et al., 2014 [72] | Y                     | Y                      | Y                      | Y                        | Y                | Y                                   | Y                  | N              | N                             | N                         | N                      |

* concerns studies with crossover design: In case of washout periods were reported, carry-over effects could be excluded, but not if washout periods were missing or not reported. All criteria except for “dietary intake documented” and “dietary restrictions” are GRADE criteria. N: no; Y: yes; ?: unclear.
4. Discussion

To the best of our knowledge, this is the first review that critically evaluates the impact of cocoa consumption on inflammatory markers on the basis of RCTs.

After consumption of cocoa-rich food, most studies observed a decrease in inflammatory biomarkers in healthy subjects after 2–6 h (Table 1). This includes a reduction in 4-series leukotrienes [43], E-selectin, and ICAM-1 in serum/plasma [46], as well as a lowered expression of CD62P on monocytes and neutrophils [44]. The reduced activation of NFκB in PBMC, indicated by the lowered ratio of P-p65/β-actin after ingestion of a water-based cocoa drink [46], suggests that cocoa flavanols can reduce the transcription of several genes encoding for inflammatory markers like ICAM-1 and E-selectin in vivo [73]. In contrast to bolus consumption, regular cocoa consumption did not change the serum/plasma concentration of VCAM-1 [52,56], ICAM-1 [56,74], IL-1β, IL-6, TNF-α [57,58], IL-8, MCP-1 [57], E-selectin [59] and CRP [51–54] in healthy subjects, except for the decrease in CRP observed by Tzounis et al. [55]. Only McFarlin et al. observed a decrease in selected parameters (haptoglobin, CD62L on monocytes, endothelial microparticles) after regular cocoa consumption. This decrease was only significant in obese subjects who had initially higher values than subjects who were normal weight or overweight [59] (Table 2).

The different results from bolus and regular consumption studies in healthy subjects raises the question of why anti-inflammatory effects were detectable after acute cocoa consumption, but not in most studies after regular cocoa consumption. First of all, we have to bear in mind that epicatechin, which is claimed to be responsible for anti-inflammatory effects after cocoa intake [31], has an elimination half-time about 2 h [75]. For this reason, anti-inflammatory effects are rather unlikely to occur in blood samples obtained after an overnight fast in regular consumption studies. On the other hand, epicatechin metabolites were found in lymphoid tissues of rats after daily cocoa feeding for three weeks [76]. Consequently, an accumulation of epicatechin in human leukocytes and also in endothelial cells by regular cocoa consumption may occur. Second, if we consider that a balanced release of vasodilating/-constricting factors and pro-/antithrombotic substances prevents vascular inflammation in healthy subjects [77], the lack of anti-inflammatory effects after regular cocoa consumption in fasting blood may be simply explained by the lack of basal inflammation. This is stressed by the results of McFarlin et al., who found anti-inflammatory effects after regular cocoa consumption only in obese participants with initially elevated inflammation markers compared to normal-weight and overweight subjects, but not in the later subgroups [59]. A range of proinflammatory adipokines are released from adipose tissue in obesity [78], but most RCTs on regular cocoa consumption did not investigate healthy subjects with obesity (Table 2).

In contrast to healthy subjects, most regular consumption trials with patients suffering from type 2 diabetes or impaired glucose tolerance found lower concentrations of ICAM-1 [64,66] and P-selectin in serum or plasma [64] and a reduced expression of VLA-4, CD36, and CD40 on monocytes [64]. Results on proinflammatory cytokines and on CRP are divergent (Table 4), but a reduction could be observed in two studies for proinflammatory cytokines [66,67] and in three studies for CRP [66–68] (Table 4). In pre-/hypertension (Table 3) and in CAD (Table 5), two studies only observed a reduction in VCAM-1 by regular cocoa consumption [60,69]. The activity of NADPH-oxidase [71] and the number of endothelial microparticles [72] decreased after acute [71] and regular consumption [72] of flavanol-rich cocoa products, respectively. However, further trials did not find any changes after acute [45,48] and regular consumption [48,51,61,62,70]. The results from different groups of participants suggest that the reaction towards cocoa consumption is different. This may be explained by the different stages of vascular inflammation. In patients with type 2 diabetes, vascular endothelial dysfunction can be partly restored by reducing inflammation [79]. In these patients, including those with impaired glucose tolerance, anti-inflammatory effects could be observed in several studies after cocoa consumption at the basal state, but also after an oral glucose challenge (Table 4). As vascular inflammation in patients with existing cardiovascular diseases is pronounced and associated with proatherogenic modifications [77], the anti-inflammatory properties of cocoa flavanols that were ingested from cocoa-rich foods might
have been too weak to reduce inflammation in pre-/hypertensive subjects and in patients with existing CAD.

The anti-inflammatory effect of cocoa depends on the dose of cocoa flavanols ingested [66], but data on total flavanol intake based on HPLC analysis of individual flavanols are only provided by single studies. As the epicatechin content in cocoa products correlates strongly with the sum of catechin, epicatechin, dimer B2, dimer B5, trimer C1, and tetramer D ($r = 0.99$) [80], epicatechin intake with cocoa reflects total flavanol intake. Therefore, the dose of epicatechin, which is believed to be responsible for the anti-inflammatory effects of cocoa consumption [31], has to be considered for the interpretation of the results. However, data on epicatechin intake were not available from all studies. Apart from the dose, efficacy on inflammatory biomarkers may depend on the food matrix. A higher bioavailability can be achieved by using a liquid matrix (cocoa drink) instead of solid chocolate, by co-administration of carbohydrates (e.g., by sugar or a carbohydrate-rich meal), and by the lack of milk protein [23]. Most studies providing flavanol-rich chocolate did not find anti-inflammatory effects [45,47,48,51,58,61,65,68] except for four studies [43,49,52,69] in which, however, only single parameters changed. On the other hand, nine out of 14 RCTs providing a flavanol-rich cocoa drink observed anti-inflammatory effects in one [44,55,57,60] or even several parameters [46,64,66,67]. However, methodological differences concerning participants (age, BMI, health status, or stage of vascular inflammation), the kind of intervention (food matrix, dose of epicatechin ingested), and the biomarkers used make a comparison between studies difficult. In regular consumption trials, the duration of cocoa treatment might also be relevant if epicatechin would accumulate in vivo. A reduction in ICAM-1 and ICAM-3 as well as a decreased expression of several adhesion molecules on leukocytes was observed after daily consumption of 70 g dark chocolate by overweight men, irrespective of whether the chocolate was enriched with flavanols or not [81]. This suggests that an epicatechin intake >97 mg through dark chocolate does not lead to stronger anti-inflammatory effects in overweight men. If other patients or foods were used, the result might have been different. For these reasons, a minimum dose that is needed to reduce inflammation cannot be ruled out.

Furthermore, the choice of parameters has to be considered when interpreting the results. CRP did not change in most studies despite the use of highly-sensitive CRP kits (Tables 1–5), which are demanded for subjects with cardiovascular risk or established cardiovascular diseases [82]. In bolus studies, the lack of changes in CRP 2 h [45,48] and 6 h [50] after bolus consumption of cocoa is not surprising as the CRP’s reaction in vivo to stimuli such as IL-1β, IL-6, and TNF-α takes about 6 h [83]. In regular consumption trials, the lack of changes in CRP indicates that cocoa consumption does not affect systemic inflammation, and the main stimuli for CRP synthesis, IL-1β, IL-6, and TNF-α, did not change in most trials. However, due to their short half-life time in vivo (for TNF-α only 5 min) and their low stability in serum or plasma samples, the concentrations in vivo may be underestimated [84]. This is likely as several adhesion molecules whose gene expression is induced by TNF-α and IL-1β [85] decreased in serum/plasma in several studies. As shown in Tables 1–5 nearly 50% of all trials found a reduction in ICAM-1 (five studies [46,49,52,64,66] out of 11 [46,49,51,52,57,60,62,64,66,69]) and in P-selectin (three studies [44,62,64] out of six [44,49,60,62,64,69]) after cocoa treatment. In contrast, VCAM-1 decreased in a single trial [60] (out of nine [46,49,52,56,57,60,62,64,69]) and E-selectin did not change in any of six RCTs [49,59,60,62,64,69]. For the interpretation of the results, it is important to consider that E-selectin and VCAM-1 are only expressed by activated endothelial cells, and P-selectin additionally by platelets, whereas ICAM-1 is expressed by a variety of cells: activated endothelial cells, but especially by unstimulated and stimulated leukocytes [85,86]. With regard to the origin of adhesion molecules in serum/plasma, the reduction of ICAM-1 and the lack of changes in VCAM-1 may reflect a reduced activation of leukocytes by cocoa. Nevertheless, caution is necessary when interpreting the results. Changes in serum/plasma may not only reflect changes in the expression of the cell surface, but also changes in the degree of shedding and/or internalization. Moreover, shed molecules may interact with counter receptors or soluble ligands, and thus may not be detected [87]. However, the reduced expression of VLA-4, CD36 (scavenger receptor of oxidized
LDL) [64], and CD62 L [59] on monocytes and the decrease in 4-series leukotrienes in plasma after cocoa consumption indicates lowered monocyte activation. This is plausible as leukotriene B$_4$ and oxidized LDL, which are known stimuli for monocytes [88], have been shown to decrease through cocoa consumption [43,89]. T cells are involved in atherogenesis [90], but their expression of LFA-1, VLA-4, and CD40 was not modulated by cocoa consumption [64], suggesting that T cells were not modulated. Thus, our results suggest that anti-inflammatory changes after cocoa consumption may be detected by cellular biomarkers (especially on monocytes) rather than by parameters in the serum/plasma. Microparticles derived from endothelium, platelets, and leukocytes induce the transcription and secretion of proinflammatory cytokines and the expression of adhesion molecules and have been considered as biomarkers of vascular injury and inflammation [91]. If we also bear in mind that both studies investigating endothelial microparticles found reduced concentrations in plasma after consumption of flavanol-rich cocoa [59,72], endothelial microparticles are promising parameters for future studies with a focus on vascular inflammation.

With regard to the study quality (Table 6), most trials considered were crossover studies using washout periods, suggesting a well-performed study design. However, allocation concealment and compliance with intervention were not always reported and participants not always blinded. Masking of participants is difficult due to the characteristic color and taste of cocoa, but it is possible, especially through the use of beverages. If we also bear in mind that inflammation was not the primary aim in most studies except for Monagas et al. [64], which is the only study with sample size calculation on the basis of inflammatory biomarkers, evidence for anti-inflammatory effects achieved by cocoa consumption is rather low.

5. Conclusions

In conclusion, consumption of flavanol-rich cocoa may reduce inflammation, probably by a reduced activation of monocytes and neutrophils. This may prevent or even reduce vascular inflammation. The efficacy of this measure probably depends on the extent of vascular inflammation, but also on the kind of cocoa product used. However, the evidence for anti-inflammatory effects of cocoa consumption is currently low. Further RCTs with inflammation as primary outcome marker are needed. These should investigate specific markers of leukocyte activation not only in the serum or plasma, but also in leukocytes. Endothelial microparticles should also be determined. Subjects suffering from low basal inflammation are of great interest as well as situations accompanied by an increased inflammatory burden (e.g., postprandial state, oral glucose tolerance test). In future trials, researchers and participants should be blinded and compliance with cocoa treatment should be determined to improve the studies’ quality.

Acknowledgments: This work was not supported by any grants. We did not receive any funds for covering the costs to publish in open access.

Author Contributions: S.E. performed the literature search and wrote the paper and interpreted the results. P.S. contributed to the interpretation of the results.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Castellon, X.; Bogdanova, V. Chronic inflammatory diseases and endothelial dysfunction. Aging Dis. 2016, 7, 81–89. [CrossRef] [PubMed]
2. Hameed, I.; Masoodi, S.R.; Mir, S.A.; Nabi, M.; Ghazanfar, K.; Ganai, B.A. Type 2 diabetes mellitus: From a metabolic disorder to an inflammatory condition. World J. Diabetes 2015, 6, 598–612. [PubMed]
3. Colak, E.; Majkic-Singh, N.; Zoric, L.; Radosavljevic, A.; Kosanovic-Jakovcic, N. The role of CRP and inflammation in the pathogenesis of age-related macular degeneration. Biochem. Med. 2012, 22, 39–48. [CrossRef]
4. Spencer, J.P.; Vafeiadou, K.; Williams, R.J.; Vauzour, D. Neuroinflammation: Modulation by flavonoids and mechanisms of action. Mol. Aspects Med. 2012, 33, 83–97. [CrossRef] [PubMed]
5. Poredos, P.; Kaja Jezovnik, M. Markers of preclinical atherosclerosis and their clinical relevance. *VASA. Z. Gefasskrankh.* 2015, 44, 247–256. [CrossRef] [PubMed]

6. Tousoulis, D.; Papageorgiou, N.; Androulakis, E.; Siassos, G.; Latsios, G.; Tentolouris, K.; Stefanadis, C. Diabetes mellitus-associated vascular impairment: Novel circulating biomarkers and therapeutic approaches. *J. Am. Coll. Cardiol.* 2013, 62, 667–676. [CrossRef] [PubMed]

7. Kenny, T.P.; Keen, C.L.; Schmitz, H.H.; Gershwin, M.E. Immune effects of cocoa procyanidin oligomers on peripheral blood mononuclear cells. *Exp. Biol. Med.* 2007, 232, 293–300.

8. Mao, T.K.; van de Water, J.; Keen, C.L.; Schmitz, H.H.; Gershwin, M.E. Modulation of TNF-α secretion in peripheral blood mononuclear cells by cocoa flavanols and procyanidins. *Dev. Immunol.* 2002, 9, 135–141. [CrossRef] [PubMed]

9. Ramiro, E.; Franch, A.; Castellote, C.; Perez-Cano, F.; Permanyer, J.; Izquierdo-Pulido, M.; Castell, M. Flavonoids from *Theobroma cacao* down-regulate inflammatory mediators. *J. Agric. Food Chem.* 2007, 53, 8506–8511. [CrossRef] [PubMed]

10. Kenny, T.P.; Shu, S.A.; Moritoki, Y.; Keen, C.L.; Gershwin, M.E. Cocoa flavanols and procyanidins can modulate the lipopolysaccharide activation of polymorphonuclear cells *in vitro*. *J. Med. Food* 2009, 12, 1–7. [CrossRef] [PubMed]

11. Ramiro, E.; Franch, A.; Castellote, C.; Andres-Lacueva, C.; Izquierdo-Pulido, M.; Castell, M. Effect of *Theobroma cacao* flavonoids on immune activation of a lymphoid cell line. *Br. J. Nutr.* 2005, 93, 859–866. [CrossRef] [PubMed]

12. Mackenzie, G.G.; Carrasquedo, F.; Delfino, J.M.; Keen, C.L.; Fraga, C.G.; Oteiza, P.I. Epicatechin, catechin, and dimeric procyanidins inhibit PMA-induced NF-κB activation at multiple steps in Jurkat T cells. *FASEB J.* 2004, 18, 167–169. [PubMed]

13. Mackenzie, G.G.; Oteiza, P.I. Modulation of transcription factor NF-κB in Hodgkin’s lymphoma cell lines: Effect of (−)-epicatechin. *Free Radic. Res.* 2006, 40, 1086–1094. [CrossRef] [PubMed]

14. Selmi, C.; Mao, T.K.; Keen, C.L.; Schmitz, H.H.; Eric Gershwin, M. The anti-inflammatory properties of cocoa flavanols. *J. Cardiovasc. Pharmacol.* 2006, 47 (Suppl. S2), 163–171. [CrossRef] [PubMed]

15. Ramiro-Puig, E.; Castell, M. Cocoa: Antioxidant and immunomodulator. *Br. J. Nutr.* 2009, 101, 931–940. [CrossRef] [PubMed]

16. Mehrinfar, R.; Frishman, W.H. Flavanol-rich cocoa: A cardioprotective nutraceutical. *Cardiol. Rev.* 2008, 16, 109–115. [CrossRef] [PubMed]

17. Schewe, T.; Kuhn, H.; Sies, H. Flavonoids of cocoa inhibit recombinant human 5-lipoxygenase. *J. Nutr.* 2002, 132, 1825–1829. [PubMed]

18. Sies, H.; Schewe, T.; Heiss, C.; Kelm, M. Cocoa polyphenols and inflammatory mediators. *Am. J. Clin. Nutr.* 2005, 81, 3045–3125. [PubMed]

19. Lee, K.W.; Kang, N.J.; Oak, M.H.; Hwang, M.K.; Kim, J.H.; Schini-Kerth, V.B.; Lee, H.J. Cocoa procyanidins inhibit expression and activation of MMP-2 in vascular smooth muscle cells by direct inhibition of MEK and MT1-MMP activities. *Cardiovasc. Res.* 2007, 79, 34–41. [CrossRef] [PubMed]

20. Fernandez-Murga, L.; Tarin, J.J.; Garcia-Perez, M.A.; Cano, A. The impact of chocolate on cardiovascular health. *Maturitas* 2011, 69, 312–321. [CrossRef] [PubMed]

21. Ding, E.L.; Huttfless, S.M.; Ding, X.; Girotra, S. Chocolate and prevention of cardiovascular disease: A systematic review. *Nutr. Metab.* 2006, 3, 2. [CrossRef] [PubMed]

22. Vogiatzoglou, A.; Mulligan, A.A.; Luben, R.N.; Lentjes, M.A.; Heiss, C.; Kelm, M.; Merx, M.W.; Spencer, J.P.; Schroeter, H.; Kuhnle, G.G. Assessment of the dietary intake of total flavan-3-ols, monomeric flavan-3-ols, proanthocyanidins and theaflavins in the European Union. *Br. J. Nutr.* 2014, 111, 1463–1473. [CrossRef] [PubMed]

23. Cifuentes-Gomez, T.; Rodriguez-Mateos, A.; Gonzalez-Salvador, I.; Alanon, M.E.; Spencer, J.P. Factors affecting the absorption, metabolism, and excretion of cocoa flavanols in humans. *J. Agric. Food Chem.* 2015, 63, 7615–7623. [CrossRef] [PubMed]

24. Desch, S.; Schmidt, J.; Kobler, D.; Sonnabend, M.; Eitel, I.; Sareban, M.; Rahimi, K.; Schuler, G.; Thiele, H. Effect of cocoa products on blood pressure: Systematic review and meta-analysis. *Am. J. Hypertens.* 2010, 23, 97–103. [CrossRef] [PubMed]
25. Hooper, L.; Kay, C.; Abdelhamid, A.; Kroon, P.A.; Cohn, J.S.; Rimm, E.B.; Cassidy, A. Effects of chocolate, cocoa, and flavan-3-ols on cardiovascular health: A systematic review and meta-analysis of randomized trials. *Am. J. Clin. Nutr.* 2012, 95, 740–751. [CrossRef] [PubMed]

26. Ried, K.; Sullivan, T.; Fakler, P.; Frank, O.R.; Stocks, N.P. Does chocolate reduce blood pressure? A meta-analysis. *BMC Med.* 2010, 8, 39. [CrossRef] [PubMed]

27. Shrime, M.G.; Bauer, S.R.; McDonald, A.C.; Chowdhury, N.H.; Collart, C.E.; Ding, E.L. Flavonoid-rich cocoa consumption affects multiple cardiovascular risk factors in a meta-analysis of short-term studies. *J. Nutr.* 2011, 141, 1982–1988. [CrossRef] [PubMed]

28. Hooper, L.; Kroon, P.A.; Rimm, E.B.; Cohn, J.S.; Harvey, I.; Le Cornu, K.A.; Ryder, J.J.; Hall, W.L.; Cassidy, A. Flavonoids, flavonoid-rich foods, and cardiovascular risk: A meta-analysis of randomized controlled trials. *Am. J. Clin. Nutr.* 2008, 88, 38–50. [PubMed]

29. Tokede, O.A.; Gaziano, J.M.; Djuusse, L. Effects of cocoa products/dark chocolate on serum lipids: A meta-analysis. *Eur. J. Clin. Nutr.* 2011, 65, 879–886. [CrossRef] [PubMed]

30. Jia, L.; Liu, X.; Bai, Y.Y.; Li, S.H.; Sun, K.; He, C.; Hui, R. Short-term effect of cocoa product consumption on lipid profile: A meta-analysis of randomized controlled trials. *Am. J. Clin. Nutr.* 2010, 92, 218–225. [CrossRef] [PubMed]

31. Corti, R.; Flammer, A.J.; Hollenberg, N.K.; Luscher, T.F. Cocoa and cardiovascular health. *Circulation* 2009, 119, 1433–1441. [CrossRef] [PubMed]

32. Grassi, D.; Desideri, G.; Croce, G.; Tiberti, S.; Aggio, A.; Ferri, C. Flavonoids, vascular function and cardiovascular protection. *Curr. Pharm. Des.* 2009, 15, 1072–1084. [CrossRef] [PubMed]

33. Grassi, D.; Desideri, G.; Necozione, S.; di Giosia, P.; Barnabei, R.; Allegaert, L.; Bernaert, H.; Ferri, C. Cocoa consumption dose-dependently improves flow-mediated dilation and arterial stiffness decreasing blood pressure in healthy individuals. *J. Hypertens.* 2015, 33, 294–303. [CrossRef] [PubMed]

34. Kirch, N.; Ellinger, S. Cocoa flavanols and cardioprotective effects. Which flavanols may contribute to vascular health? *Ernährung. Umsch.* Int. 2014, 61, 144–151.

35. Ellinger, S.; Reusch, A.; Stehle, P.; Helfrich, H.P. Epicatechin ingested via cocoa products reduces blood pressure in humans: A nonlinear regression model with a bayesian approach. *Am. J. Clin. Nutr.* 2012, 95, 1365–1377. [CrossRef] [PubMed]

36. Schroeter, H.; Heiss, C.; Balzer, J.; Kleinborgard, P.; Keen, C.L.; Hollenberg, N.K.; Sies, H.; Kwik-Uribe, C.; Schmitz, H.H.; German, J.B.; Keen, C.L. Chocolate procyanidins decrease the leukotriene-prostacyclin ratio in humans and human aortic endothelial cells. *Am. J. Clin. Nutr.* 2001, 73, 36–40. [PubMed]
44. Heptinstall, S.; May, J.; Fox, S.; Kwik-Uribe, C.; Zhao, L. Cocoa flavanols and platelet and leukocyte function: Recent in vitro and ex vivo studies in healthy adults. J. Cardiovasc. Pharmacol. 2006, 47 (Suppl. S2), 197–205. [CrossRef]

45. Flammer, A.J.; Hermann, F.; Sudano, I.; Spieler, K.; Hermann, M.; Cooper, K.A.; Serafini, M.; Luscher, T.F.; Ruschitzka, F.; Noll, G.; et al. Dark chocolate improves coronary vasomotion and reduces platelet reactivity. Circulation 2007, 116, 2376–2382. [CrossRef] [PubMed]

46. Vazquez-Agell, M.; Urpi-Sarda, M.; Sacanella, E.; Camino-Lopez, S.; Chiva-Blanch, G.; Llorente-Cortes, V.; Tobias, E.; Roura, E.; Andres-Lacueva, C.; Lamuela-Raventos, R.M.; et al. Cocoa consumption reduces NF-kB activation in peripheral blood mononuclear cells in humans. Nutr. Metab. Cardiovasc. Dis. 2013, 23, 257–263. [CrossRef] [PubMed]

47. Davison, G.; Callister, R.; Williamson, G.; Cooper, K.A.; Gleeson, M. The effect of acute pre-exercise dark chocolate consumption on plasma antioxidant status, oxidative stress and immunoenocrine responses to prolonged exercise. Eur. J. Nutr. 2012, 51, 69–79. [CrossRef] [PubMed]

48. Flammer, A.J.; Sudano, I.; Wolfrum, M.; Thomas, R.; Enseleit, F.; Periat, D.; Kaiser, P.; Hirt, A.; Hermann, M.; Serafini, M.; et al. Cardiovascular effects of flavanol-rich chocolate in patients with heart failure. Eur. Heart J. 2012, 33, 2172–2180. [CrossRef] [PubMed]

49. Mellor, D.D.; Madden, L.A.; Smith, K.A.; Atkin, S.L. High-polyphenol chocolate reduces endothelial dysfunction and oxidative stress during acute transient hyperglycaemia in type 2 diabetes: A pilot randomized controlled trial. Diabet. Med. 2013, 30, 478–483. [CrossRef] [PubMed]

50. Basu, A.; Betts, N.M.; Leyva, M.J.; Fu, D.; Aston, C.E.; Lyons, T.J. Acute cocoa supplementation increases postprandial HDL cholesterol and insulin in obese adults with type 2 diabetes after consumption of a high-fat breakfast. J. Nutr. 2015, 145, 2325–2332. [CrossRef] [PubMed]

51. Grassi, D.; Necozione, S.; Lippi, C.; Croce, G.; Valeri, L.; Pasqualetti, P.; Desideri, G.; Blumberg, J.B.; Ferri, C. Cocoa reduces blood pressure and insulin resistance and improves endothelium-dependent vasodilation in hypertensives. Hypertension 2005, 46, 398–405. [PubMed]

52. Kurlandsky, S.B.; Stote, K.S. Cardioprotective effects of chocolate and almond consumption in healthy women. Nutr. Res. 2006, 26, 509–516. [CrossRef]

53. Crews, W.D., Jr.; Harrison, D.W.; Wright, J.W. A double-blind, placebo-controlled, randomized trial of the effects of dark chocolate and cocoa on variables associated with neuropsychological functioning and cardiovascular health: Clinical findings from a sample of healthy, cognitively intact older adults. Am. J. Clin. Nutr. 2008, 87, 872–880. [PubMed]

54. Njike, V.Y.; Faridi, Z.; Shuval, K.; Dutta, S.; Kay, C.D.; West, S.G.; Kris-Etherton, P.M.; Katz, D.L. Effects of chocolate consumption on plasma antioxidant status, oxidative stress and immunoenocrine responses to consumption of ready-to-eat meals supplemented with cocoa extract within a hypocaloric diet. Nutr. Metab. Cardiovasc. Dis. 2014, 24, 416–422. [CrossRef] [PubMed]

55. Tzounis, X.; Rodriguez-Mateos, A.; Vulevic, J.; Gibson, G.R.; Kwik-Uribe, C.; Spencer, J.P. Prebiotic evaluation of cocoa-derived flavanols in healthy humans by using a randomized, controlled, double-blind, crossover intervention study. Am. J. Clin. Nutr. 2011, 93, 62–72. [CrossRef] [PubMed]

56. Ibero-Baraibar, I.; Abete, I.; Navas-Carretero, S.; Massis-Zaid, A.; Martinez, J.A.; Zulet, M.A. Oxidised LDL prevents secretion of pro-inflammatory cytokines and activates peripheral blood mononuclear cells in humans. J. Nutr. Biochem. 2013, 24, 626–632. [CrossRef] [PubMed]

57. Sarria, B.; Martinez-Lopez, S.; Sierra-Cinos, J.L.; Garcia-Diz, L.; Mateos, R.; Bravo, L. Regular consumption of a cocoa product improves the cardiometabolic profile in healthy and moderately hypercholesterolaemic adults. Br. J. Nutr. 2014, 111, 122–134. [CrossRef] [PubMed]

58. West, S.G.; Mcintyre, M.D.; Piotrowski, M.J.; Poupin, N.; Miller, D.L.; Preston, A.G.; Wagner, P.; Groves, L.F.; Skulas-Ray, A.C. Effects of dark chocolate and cocoa consumption on endothelial function and arterial stiffness in overweight adults. Br. J. Nutr. 2014, 111, 653–661. [CrossRef] [PubMed]

59. McFarlin, B.K.; Venable, A.S.; Henning, A.L.; Prado, E.A.; Best Sampson, J.N.; Vijg, J.R.; Hill, D.W. Natural cocoa consumption: Potential to reduce atherogenic factors? J. Nutr. Biochem. 2015, 26, 626–632. [CrossRef] [PubMed]
61. Grassi, D.; Desideri, G.; Necozione, S.; Lippi, C.; Casale, R.; Properzi, G.; Blumberg, J.B.; Ferri, C. Blood pressure is reduced and insulin sensitivity increased in glucose-intolerant, hypertensive subjects after 15 days of consuming high-polyphenol dark chocolate. *J. Nutr.* 2008, 138, 1671–1676. [PubMed]

62. Muniyappa, R.; Hall, G.; Kolodziej, T.L.; Karne, R.J.; Crandon, S.K.; Quon, M.J. Cocoa consumption for 2 wk enhances insulin-mediated vasodilation without improving blood pressure or insulin resistance in essential hypertension. *Am. J. Clin. Nutr.* 2008, 88, 1685–1696. [CrossRef] [PubMed]

63. Balzer, J.; Rassaf, T.; Heiss, C.; Kleinbongard, P.; Lauer, T.; Merx, M.; Heussen, N.; Gross, H.B.; Keen, C.L.; Schroeter, H.; et al. Sustained benefits in vascular function through flavanol-containing cocoa in medicated diabetic patients a double-masked, randomized, controlled trial. *J. Am. Coll. Cardiol.* 2008, 51, 2141–2149. [CrossRef] [PubMed]

64. Monagas, M.; Khan, N.; Andres-Lacueva, C.; Casas, R.; Urpi-Sarda, M.; Llorach, R.; Lamuela-Raventos, R.M.; Estruch, R. Effect of cocoa powder on the modulation of inflammatory biomarkers in patients at high risk of cardiovascular disease. *Am. J. Clin. Nutr.* 2009, 90, 1144–1150. [CrossRef] [PubMed]

65. Mellor, D.D.; Sathyapalan, T.; Kilpatrick, E.S.; Atkin, S.L. High-cocoa polyphenol-rich chocolate improves HDL cholesterol in Type 2 diabetes patients. *Diabet. Med.* 2010, 27, 1318–1321. [CrossRef] [PubMed]

66. Rostami, A.; Khalili, M.; Haghighat, N.; Eghtesadi, M. High-cocoa polyphenol-rich chocolate improves blood pressure in patients with diabetes and hypertension. *ARYA Atheroscler.* 2015, 11, 21–29. [PubMed]

67. Parsaeyan, N.; Mozaffari-Khosravi, H.; Absalan, A.; Mozayan, M.R. Beneficial effects of cocoa on lipid peroxidation and inflammatory markers in type 2 diabetic patients and investigation of probable interactions of cocoa active ingredients with prostaglandin synthase-2 (PTGS-2/COX-2) using virtual analysis. *J. Diabetes Metab. Disord.* 2014, 13, 30. [CrossRef] [PubMed]

68. Heiss, C.; Jahn, S.; Taylor, M.; Real, W.M.; Angeli, F.S.; Wong, M.L.; Amabile, N.; Prasad, M.; Rassaf, T.; Ottaviani, J.I.; et al. Improvement of endothelial function with dietary flavanols is associated with mobilization of circulating angiogenic cells in patients with coronary artery disease. *J. Am. Coll. Cardiol.* 2010, 56, 218–224. [CrossRef] [PubMed]

69. Hoffrêdo, L.; Perri, L.; Catasca, E.; Pignatelli, P.; Brancorsini, M.; Nocella, C.; De Falco, E.; Bartimoccia, S.; Frati, G.; Carnevale, R.; et al. Dark chocolate acutely improves walking autonomy in patients with peripheral artery disease. *J. Am. Heart Assoc.* 2014, 3, e001072. [CrossRef] [PubMed]

70. Horn, P.; Amabile, N.; Angeli, F.S.; Sansone, R.; Stegeman, B.; Kelm, M.; Springer, M.L.; Yeghiazarians, Y.; Schroeter, H.; Heiss, C. Dietary flavanol intervention lowers the levels of endothelial microparticles in coronary artery disease patients. *Br. J. Nutr.* 2014, 111, 1245–1252. [CrossRef] [PubMed]

71. Brasier, A.R. The nuclear factor-κB -interleukin-6 signalling pathway mediating vascular inflammation. *Cardiovasc. Res.* 2010, 86, 211–218. [CrossRef] [PubMed]

72. Grassi, D.; Lippi, C.; Necozione, S.; Desideri, G.; Ferri, C. Short-term administration of dark chocolate is followed by a significant increase in insulin sensitivity and a decrease in blood pressure in healthy persons. *Am. J. Clin. Nutr.* 2005, 81, 611–614. [PubMed]

73. Richelle, M.; Tavazzi, I.; Enslen, M.; Offord, E.A. Plasma kinetics in man of epicatechin from black chocolate. *Eur. J. Clin. Nutr.* 1999, 53, 22–26. [CrossRef] [PubMed]

74. Urpi-Sarda, M.; Ramiro-Puig, E.; Khan, N.; Ramos-Romero, S.; Llorach, R.; Castell, M.; Gonzalez-Manzano, S.; Santos-Buelga, C.; Andres-Lacueva, C. Distribution of epicatechin metabolites in lymphoid tissues and testes of young rats with a cocoa-enriched diet. *Br. J. Nutr.* 2010, 103, 1393–1397. [CrossRef] [PubMed]

75. Chistiakov, D.A.; Orekhov, A.N.; Bobryshev, Y.V. Endothelial barrier and its abnormalities in cardiovascular disease. *Front. Physiol.* 2015, 6, 365. [CrossRef] [PubMed]

76. Gu, P.; Xu, A. Interplay between adipose tissue and blood vessels in obesity and vascular dysfunction. *Rev. Endocr. Metab. Disord.* 2013, 14, 49–58. [CrossRef] [PubMed]
79. Roberts, A.C.; Porter, K.E. Cellular and molecular mechanisms of endothelial dysfunction in diabetes. *Diabetes Vasc. Dis. Res.* 2013, 10, 472–482. [CrossRef] [PubMed]

80. Cooper, K.A.; Campos-Gimenez, E.; Jimenez Alvarez, D.; Nagy, K.; Donovan, J.L.; Williamson, G. Rapid reversed phase ultra-performance liquid chromatography analysis of the major cocoa polyphenols and inter-relationships of their concentrations in chocolate. *J. Agric. Food Chem.* 2007, 55, 2841–2847. [CrossRef] [PubMed]

81. Esser, D.; Mars, M.; Oosterink, E.; Stalmach, A.; Muller, M.; Afman, L.A. Dark chocolate consumption improves leukocyte adhesion factors and vascular function in overweight men. *FASEB J.* 2014, 28, 1464–1473. [CrossRef] [PubMed]

82. Pearson, T.A.; Mensah, G.A.; Alexander, R.W.; Anderson, J.L.; Cannon, R.O., III; Criqui, M.; Fadl, Y.Y.; Fortmann, S.P.; Hong, Y.; Myers, G.L.; *et al.* Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the centers for disease control and prevention and the american heart association. *Circulation* 2003, 107, 499–511. [CrossRef] [PubMed]

83. Thomas, L. C-reaktives protein. In *Labor und Diagnose*, 8th ed.; Thomas, L., Ed.; TH-Books Verlagsgesellschaft: Frankfurt, Germany, 2012; Volume 2, pp. 1308–1328. (In German)

84. Thomas, L. Zytokine und zytokinrezeptoren. In *Labor und Diagnose*, 8th ed.; Thomas, L., Ed.; TH-Books-Verlagsgesellschaft: Frankfurt, Germany, 2012; Volume 2, pp. 1278–1291. (In German)

85. Lebranchu, Y.; Valentin, J.F.; Büchler, M.F. Measurement of soluble adhesion molecules in biological fluids. In *Adhesion Molecules in Health and Disease*; Paul, L.C., Issekutz, T.B., Eds.; Marcel Dekker: New York, NY, USA, 1997; pp. 87–122.

86. Janeway, C.A.; Travers, P. *Immunologie*, 2nd ed.; Spektrum Akademischer Verlag: Heidelberg, Germany, 1997. (In German)

87. Paul, L.C.; Issekutz, T.B. *Adhesion Molecules in Health and Disease*; Marcel Dekker: New York, NY, USA, 1997.

88. Gratchev, A.; Sobenin, I.; Orekhov, A.; Kzhyshkowska, J. Monocytes as a diagnostic marker of cardiovascular diseases. *Immunobiology* 2012, 217, 476–482. [CrossRef] [PubMed]

89. Scheid, L.; Reusch, A.; Stehle, P.; Ellinger, S. Antioxidant effects of cocoa and cocoa products *ex vivo* and *in vivo*: Is there evidence from controlled intervention studies? *Curr. Opin. Clin. Nutr. Metab. Care* 2010, 13, 737–742. [CrossRef] [PubMed]

90. Ketelhuth, D.F.; Hansson, G.K. Cellular immunity, low-density lipoprotein and atherosclerosis: Break of tolerance in the artery wall. *Thromb. Haemost.* 2011, 106, 779–786. [CrossRef] [PubMed]

91. Lovren, F.; Verma, S. Evolving role of microparticles in the pathophysiology of endothelial dysfunction. *Clin. Chem.* 2013, 59, 1166–1174. [CrossRef] [PubMed]

© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).